This keynote presentation was given at the global Bio-Connect Conference at the World Trade Centre Morelos in Cuernavaca, Mexico on November 29, 2011. The presentation highlighted the MaRS Life Sciences / Healthcare portfolio, the EXCITE pre-market assessment initiative in the Ontario healthcare system, and the role that MaRS Innovation plays to expedite the commercial outcomes from the intellectual property out of Canada's leading research and academic institutions.

1. Building Canada’s next generation of
growth companies
Driving Commercial Outcomes from
Innovation and Technology - The MaRS
Discovery District Case Study
November 29th 2011

2. There are three objectives that I hope to achieve in
today’s presentation:
1. Provide an overview of MaRS, our mandate, and
the programs and services we offer
2. Discuss the MaRS Life Sciences and Healthcare
Practice, MaRS Innovation, and the MaRS
EXCITE program
3. Provide an opportunity to address any questions
you may have
2

3. MaRS is a non-profit innovation centre connecting science,
technology and social entrepreneurs with business skills,
networks and capital
MaRS helps to create successful global
Mission businesses from Canada s science and
technology
Who we Early stage science and technology ventures
Serve and innovative social purpose businesses
Measure of
Job and wealth creation for the economy
Success
3

5. 5

7. Discovery
Details in
Notes Part of
Slide

8. pg
8

9. Phase I"
Phase II"

10. Discovery District Financial District Creative & Arts District
Gardiner Museum of Ceramic Art
Royal Conservatory of Music
Royal Ontario Museum
Women’s College
University of Toronto
The MaRS Centre
UHN Toronto General
UHN Princess Margaret Hospital for Sick children
Mount Sinai
Ryerson
Toronto Rehab
University
Art Gallery of Ontario
TIFF & OCAD
Four Seasons Centre
Financial District
Entertainment District
10

11. pg
11

12. Improving
Commercialization Building Next Generation
Output from Academe Startups
12

13. MaRS Innovation
13

14. ¨ A professionally managed, business accelerator platform as a
single point of entry for industry partners and investors
¨ Funding of MaRS Innovation and distribution of revenues are
based upon an agreed upon formula amongst all member
institutions
¨ Currently trending with approximately 300 disclosures per
year, approximately 70% of which are life sciences, medical
device, or healthcare IT sectors
¨ Cash contributions from member institutions are based pro-
rata on the annual research budget for each institution
14

15.
Business Advice Education Access
and Mentorship" and Insight" to Capital"
" "
Advisors" Entrepreneurship Education Angels"
Volunteers" Market Research" Venture Capital"
" Thought Leadership" Corporations"
Government Programs"
Foundations"
"
Networks, Talent, Customers and Partners"
Programs for High Growth Ventures, Policy Initiatives, and Special Projects "
15

16. Life Sciences
and | ICE | Cleantech | Social
Healthcare
Intellectual Property Strategic Partnerships Marketing & Sales
Financing Due Diligence Strategy and Business Planning
Market/Competitive Intelligence Human Resources and Talent Management
Product Development and Marketing Legal Corporate Governance
Operations and Process Customer Relationship Management
Financial Management, Accounting, Tax
MaRS Advisors | Partners | Volunteers
16

17. ¨ Approximately 125 active ventures in the MaRS portfolio,
working with an array of mentors and advisors
¨ Provision of market intelligence, educational resources, and
continuing to build strong connections to capital and market
opportunities
¨ Highly integrated and supportive of MaRS Innovation clients;
pipeline of high quality deal flow
Logoʼs from ArcticDX, Profound Medical, "
Pg 17

18. Licensing & Industry
Co-development "
Start-ups"
Single Commercialization Business Accelerator
Storefront for Toronto’s for Ontario’s Emerging
Academic Institutions Companies
Member Institutions" Entrepreneurs from
across Ontario and
the country"
18

19. Memory at Work
Currently there is limited crosstalk during the
development process can mean greatly protracted
timelines before new technologies are adopted or even
a reluctance to adopt new technologies
NEW
TECHNOLOGIES"
END USERS"
19
Pg 19

20.
NOW"
New Canadian " New Canadian and International"
Medical Technologies" Medical Technologies"
Unrealized
improvements Pre-market feedback loop"
Demand " More relevant
disconnect"
" technologies"
"
"
A novel approach that matches health technology innovation
with patient needs and health system priorities"
" 20

21. Memory at Work
Technology Market Sub-optimal Adoption
Development" Approval" by Health Systems"
Current
Evaluation
Process"
Pre-Market" Post-Market"
Evaluation" Evaluation"
(Risk-Based)" (Evidence-Based)"
Technology Development with Market Optimal Adoption by
Evaluation Improvements" Approval" Health Systems"
EXCITE Pre-
Incorporates technology
Market
improvements"
Evaluation
Reflects health care
Process" Pre-Market" priorities"
Evaluation" "
(Evidence-Based)"
21

22. Impact"
Real Estate Services " Ecosystem Development"
Office & Laboratory Facilities | MaRS Incubator " Strategic Partnerships | Stakeholder Support"
MaRS Collaboration Centre l " IT/AV Services" Community Programs |" Awards & Recognition"
MaRS Centre Development " Talent & Knowledge Management "
Public Policy "
Business Services"
IP Development |" Market Intelligence |" Capital & Investment"
MaRS Advisory |" Entrepreneurship Education"
22

23. Don Duval"
Email: dduval@marsdd.com"
Twitter: don_duval"
Speakerfile: don.duval"